A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor Clinical Trial

Official title:

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Preliminary Efficacy of 9MW3811 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05911984
• Other study ID #: 9MW3811-2023-CP102
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: June 30, 2023
• Est. completion date: March 2024

Study information

• Verified date: June 2023
• Source: Mabwell (Shanghai) Bioscience Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 27
• Est. completion date: March 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female participants between 18 and 75 years of age, inclusive.

2. Histologically or cytologically confirmed advanced malignant solid tumors, for which standard therapy does not exist or has proven ineffective or intolerable.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Life expectancy of = 3 months.

5. Participants must have measurable disease according to RECIST (version 1.1).

6. Adequate organ functions.

7. Sexually active fertile participants, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.

Exclusion Criteria:

1. Participants with cancerous meningitis and/or central nervous system metastases with clinical symptoms.

2. History of other active malignant tumor within 3 years prior to screening.

3. Suffering from poorly controlled body cavity effusion.

4. Suffering from active autoimmune disease.

5. History of chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, or other respiratory diseases that require hospitalization within 4 weeks prior to the first dose of study drug.

6. History of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.

7. History of other severe or uncontrolled systemic disease, i.e. poorly controlled diabetes.

8. Previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.

9. Major surgery within 28 days prior to the first dose of study drug.

10. Participants with one or more clinically significant positive test results of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, treponema pallidum antibody or human immunodeficiency virus (HIV) antibody.

11. Participants who have received treatment with biotherapy, endocrine therapy, immunotherapy, or other anti-tumor therapy within 2 weeks prior to the first dose of study drug; Radical radiotherapy received within 3 weeks or palliative radiotherapy received within 2 weeks prior to the first dose of study drug; Received treatment with chemotherapy within 3 weeks prior to the first dose of study drug (6 weeks for nitrosourea or mitomycin); Received treatment with oral fluorouracil or small molecule targeted drugs within 2 weeks or 5 half-lives prior to the first dose of study drug (whichever is shorter); Received treatment with anti-tumor traditional Chinese medicine within 1 week prior to the first dose of study drug; Participated in other clinical trials within 4 weeks prior to the first dose of study drug.

12. Participants who have received systemic treatment with immunosuppressants within 2 weeks prior to the first dose of study drug.

Related Conditions & MeSH terms

• Advanced Malignant Solid Tumor
• Neoplasms

Intervention

Drug:
• 9MW3811 Injection
Intravenous injection

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Mabwell (Shanghai) Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs) as assessed by CTCAE v5.0	An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.	up to 24 weeks
Primary	Incidence of dose-limiting toxicity (DLT) as assessed by CTCAE v5.0	A DLT is defined as any of the adverse drug reactions listed in the protocol that will be assessed during Cycle 1	Cycle 1 Day 1 to Cycle 1 Day 21
Secondary	Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators	To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Disease Control Rate (DCR), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators	To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Duration of Response (DoR), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators	To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Progression Free Survival (PFS), According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 evaluated by investigators	To determine the preliminary efficacy of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Maximum Plasma Concentration (Cmax)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Time to reach Cmax (Tmax)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Area under the plasma concentration versus time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Terminal elimination half-life (t1/2)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	AUC from time 0 extrapolated to infinity (AUC0-inf)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Terminal elimination rate constant (?z)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Apparent clearance (CL)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Volume of distribution (Vz)	To determine the pharmacokinetic (PK) of 9MW3811 following single ascending intravenous doses in patients with advanced solid tumors.	up to 24 weeks
Secondary	Incidence of antidrug antibodies (ADA) at specified timepoints relative to baseline	To determine the immunogenicity of 9MW3811.	up to 24 weeks